The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
".. turning out to be a sad day for traders who bought yesterday hoping for a quick profit" - there you go, fixed it for you Rooster.
Indeed. BHP price is currently 1828p - which, give or take, would give me around 380 shares. Their last divi was 42p, so about £160 a year. To get that from Sirius would require a divi of around 0.5p. I'm hoping for somewhat more.
If we make it through the next year I think we'll really deserve to succeed. Throughout the last two years the terrific science and the positive response from clients from China to India to UAE to Cape Town to Mexico and the US seems to have been met with complete scepticism from investors, resulting in prolonged sp fall and a somewhat derisory response to last November's open offer. Trying to stay optimistic I think we've got big enough partners now who would want us to keep going and eventually licensing revenue will begin to flow - followed by happy days all around. I also hold Rene, which had also fallen over 90 per cent for me but with further good news today has risen some 700 per cent in the last few weeks - so it can happen!
There's no much to say though is there? A good business, consistently making money and paying good divis. Not much is going to change week to week, month to month here. Today's fall? Going XD. All expected, move along.
500p. Walked past Greggs about 8 years back - saw a queue. Bought shares. It's not the most sophisticated strategy but it worked.
"say they invested at £6/share (6p in old money)" - that would be very much worse case scenario, no? If they've got an average of 3p/£3 and are happy with 6 bags, then £18 would do it. Anyway, that's not a calculation I'm looking at - £10 and I'm outta here. I'd say it's correct to think the really big rise will only come when products are approved and being sold.
Can't answer that other than to say our bottom line has been rising very nicely over the three years and this can only help us to reach our target of moving to profitability at some point in 2020. When dermapure was launched we got these messages regularly as the sales team went about their business in raising awareness of the product. I think we have sales evidence now to conclude our product is accepted by the market and obviously every purchasing group that takes us on is good news. Hope we can crack Europe next.
Suffered? Well there was a time not so long ago when we were worth 50 times this sp. I suppose legislation wouldn't hurt, but I just think the market doesn't believe we can make inroads into the market before we run out of money. I could make a case for saying we will - the link with Chinese giants, the progress with tanneries, the increasing sense of water crisis in places such as South Africa and California - but I must admit I'm feeling worn down and fast running out of optimism here. Not going to sell up - no point at this level - so just hope someone somewhere is preparing the rabbit and the hat.
In other news announced today, Spirit have started producing at their Norwegian Oda site five months ahead of schedule. This is put down to "efficient drilling and cooperation with suppliers". Hope it goes as well in Warwick.
Nice puff piece in Rotherham local press today - the company now claiming xfiltra could be bigger for us than XOrbs, and that deals are coming this year. https://www.thestar.co.uk/business/rotherham-laundry-firm-set-to-clean-up-with-new-plastic-pollution-filter-1-9628169
"So where does a dividend to shareholders come from here?" - Have always thought if we ever are to get a dividend here it would be in form of special divi in the wake of one of the "blockbuster exits" we were taking about earlier. But not convinced it will ever happen.
"they need to release more PR updates to keep a more positive profile to maintain shareholder interest."
True, but there have now been four positive rns based on clinical progress already this year - so things have started to improve.
RNSS says first patient dosed in phase 3 trial for Ridinilazole. Going to take two and half years for the full data so patience as well as patients required, but there's every reason to hope this will do the job. I hope something else in our pipeline will come forward to keep the interest levels up - gonorrhea drug sounds promising and necessary.
"A blockbuster exit would help." I hear ya. Oxford Nanopore is the obvious candidate I suppose. Neil Woodford - not in fashion right now I know - remains very bullish on this with saying that with it's rapidly growing customer base and increasing global reach "We are very confident that the company is poised to deliver strong growth in the years ahead." I don't thing IP wants to hang around for years ahead, but obviously also it will wait until it can get a good price.
Last June our 18 per cent holding was valued at £274 million- some five times larger than our next most valuable holding. So it's pretty high stakes. But I take your points about management here - a sign that there was intention to return value to shareholders would be welcome.
Because we discovered our DMD drug did not work. You can find out more by looking at the RNS feed for the time.
I'm actually rather excited by this update, more than the market anyway. Ok it's not quite an oil discovery or a successful stage 2 results for a wonder drug, but as an LTH here it does mean the growth predicted for the company over the last four/five years is actually starting to materialise. When our income is just a few hundred thousand, you know that even an 80 per cent growth in sales is still going to leave us a tiny company and projections of $20 million income seem very distant. Now an 80 per cent growth in dermapure alone takes us from 1.9m to 3.4m - and overall we are up to 11.6m revenue. In other words - we may not be in profit yet, but it's happening people It's happening.